Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

NCT04637009 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04637009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04637009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 21, 2020
Completion date
February 20, 2023
Enrollment
20 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic/myeloproliferative neoplasm, myeloproliferative neoplasm